+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Antithrombin Market by Type (Alpha, Beta), Source (Human Plasma, Recombinant), Form, Dosage Form, Therapeutic Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904661
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antithrombin Market grew from USD 750.49 million in 2024 to USD 785.32 million in 2025. It is expected to continue growing at a CAGR of 4.71%, reaching USD 989.56 million by 2030.

Comprehensive Overview of the Antithrombin Market Dynamics Highlighting the Role of Key Biomarkers and Therapeutic Implications for Stakeholders

Antithrombin serves as an essential serine protease inhibitor that tightly regulates the blood coagulation cascade. Its delicate balance within the circulatory system determines the threshold for thrombus formation, thereby influencing patient outcomes across a broad spectrum of hemostatic disorders. As research unfolds, antithrombin’s molecular architecture and inhibitory kinetics have become central to the development of both diagnostic assays and targeted therapies.

The clinical significance of antithrombin extends beyond congenital and acquired deficiencies, encompassing complex conditions such as sepsis associated coagulopathy and disseminated intravascular coagulation. Loss of functional antithrombin activity can exacerbate systemic inflammation and contribute to multiorgan failure. Consequently, healthcare providers and pharmaceutical developers alike are investing in refined measurement techniques alongside novel formulations to restore homeostasis in critical care settings.

Recent breakthroughs in protein engineering and recombinant expression systems have opened new avenues for scalable antithrombin production. Transitioning from traditional extraction from human plasma to sophisticated cell culture platforms promises enhanced purity, batch-to-batch consistency, and reduced immunogenic risk. In parallel, formulation scientists are optimizing liquid and powder presentations to improve shelf stability and patient adherence.

This executive summary collates key insights into the shifting landscape of antithrombin research and commercialization. It articulates transformative trends, segmentation dynamics, regional characteristics, leading corporate strategies, and methodological rigor. By synthesizing these elements, decision makers will gain a comprehensive perspective to navigate emerging opportunities and challenges within the antithrombin arena.

Exploration of Pivotal Changes Reshaping Antithrombin Therapeutics Driven by Technological Innovations and Personalized Healthcare Advances

The antithrombin space is undergoing profound transformation driven by technological convergence and evolving clinical paradigms. Emerging gene editing platforms are challenging conventional notions of protein replacement, as researchers pursue genome correction strategies to restore endogenous antithrombin synthesis. Meanwhile, advances in bioinformatics and molecular modeling are accelerating the discovery of engineered antithrombin variants with augmented inhibitory profiles or extended half lives.

Concurrently, personalized medicine frameworks are integrating antithrombin profiling into precision therapeutics. Adaptive clinical trials now stratify patients based on genetic predisposition and functional antithrombin levels, enabling targeted dosing regimens that minimize bleeding complications while maximizing efficacy. This shift from one-size-fits-all approaches to patient-centric care pathways has redefined both regulatory expectations and commercial value propositions.

In parallel, digital health platforms are enhancing real-time monitoring of antithrombin activity. Wearable sensors and point-of-care diagnostics feed into interoperable data ecosystems, providing clinicians with actionable intelligence on coagulation status. As a result, treatment protocols can be adjusted instantaneously, reducing adverse events and improving overall outcomes.

Altogether, these cumulative shifts underscore a paradigm in which antithrombin research is no longer siloed but integrated across genetic engineering, digital diagnostics, and personalized treatment algorithms. Stakeholders prepared to embrace these convergent trends will secure a competitive edge in the next generation of coagulation management.

Comprehensive Assessment of the Cumulative Consequences of 2025 United States Trade Tariffs on Antithrombin Production and Supply Chain Resilience

The imposition of new trade tariffs by the United States in 2025 has introduced complex layers of cost and compliance for antithrombin supply chains. Historically, a significant portion of plasma-derived antithrombin raw material has been imported under preferential tariff agreements. Disruption of these arrangements has elevated landed costs, prompting manufacturers to reevaluate sourcing strategies and contractual structures.

In response, many producers have diversified their supply portfolios, securing alternative plasma supply chains within tariff-exempt jurisdictions and expanding domestic collection capabilities. This realignment has mitigated some margin pressures but has also necessitated enhanced logistics coordination and regulatory navigation to ensure uninterrupted product flow. Transitional clauses within tariff legislation have offered temporary relief, yet long-term resilience requires deeper investment in manufacturing flexibility.

Moreover, recombinant antithrombin producers have leveraged the new tariff environment to strengthen their market positioning. Without reliance on human plasma imports, they have reinforced their value narrative around consistent supply security. Consequently, pricing differentials between recombinant and plasma-derived products have compressed, altering competitive dynamics and influencing procurement decisions by hospitals and clinics.

Overall, the cumulative impact of 2025 tariffs extends beyond mere cost increments. It has catalyzed a strategic shift toward supply chain diversification, accelerated adoption of recombinant technologies, and spurred collaborative frameworks between raw material suppliers, contract manufacturers, and end users to safeguard continuity in antithrombin availability.

InDepth Examination of Antithrombin Market Segmentation Spanning Type Source Form Dosage Form Therapeutic Application and End User Perspectives

An in-depth understanding of antithrombin market segmentation reveals critical drivers behind therapeutic innovation and commercialization strategies. When evaluating the molecular variants, alpha antithrombin and beta antithrombin offer distinct functional profiles with implications for dosing protocols and patient response variability. Recognition of these subtypes informs both clinical trial design and downstream manufacturing complexity.

Parallel examination of raw material origins highlights the divergence between human plasma and recombinant sources. Human plasma remains a traditional cornerstone, valued for its physiological fidelity, whereas recombinant production affords enhanced consistency, elimination of variable donor pools, and potential for engineered enhancements. This dichotomy underpins supply decisions and regulatory pathways across different geographies.

Further segmentation by presentation medium underscores the operational considerations between liquid and powder formulations. Liquid preparations facilitate immediate clinical use, particularly in acute settings, whereas powder forms offer logistical advantages in storage stability and reconstitution at point of care. Consequently, formulation selection intersects with hospital pharmacy operations and procurement practices.

Exploring dosage form segmentation reveals that injectable delivery remains predominant in intensive care and surgical prophylaxis, while emerging oral suspensions are seeking niches in outpatient management and pediatric applications. Therapeutic application distinctions spanning acquired deficiency, acute pancreatitis, congenital deficiency, disseminated intravascular coagulation, liver disease, and sepsis associated coagulopathy each require tailored clinical protocols that influence overall market adoption trajectories. End user perspectives-encompassing ambulatory surgical centers, clinics, diagnostic laboratories, hospitals, and research institutes-further refine demand forecasts by mapping usage patterns across acute care, outpatient settings, specialized diagnostic services, and preclinical research activities.

Strategic Regional Insights into Antithrombin Trends across the Americas Europe Middle East and Africa and AsiaPacific Markets Driving Growth Opportunities

Regional landscapes in the antithrombin domain are characterized by divergent regulatory paradigms, healthcare infrastructure maturity, and patient demographics. In the Americas, well-established plasma collection networks and advanced intensive care frameworks have historically anchored demand. Recent policy shifts and reimbursement reforms continue to shape product adoption, especially as hospitals integrate real-time coagulation monitoring into standard protocols.

Meanwhile, Europe, the Middle East and Africa encompass a spectrum of markets, from highly regulated Western Europe to emerging economies in North Africa and the Gulf. Regulatory harmonization efforts in Europe facilitate cross-border clinical trials and centralized approvals, while localized plasma collection challenges in certain regions create opportunities for recombinant alternatives and public-private partnerships aimed at bolstering biomanufacturing capacity.

Across the Asia-Pacific region, rapid growth in hospital infrastructure, rising prevalence of coagulation disorders, and increasing awareness among clinicians are driving interest in advanced antithrombin products. Government initiatives to strengthen critical care capabilities and public health investments in sepsis management further accelerate market evolution. Concurrently, rising domestic biopharma capabilities in countries such as China, Japan, and India promise to introduce new players, competitive pricing structures, and potential export dynamics.

Taken together, these regional dynamics underscore the necessity for tailored market entry strategies, regulatory intelligence, and investment in localized partnerships. Stakeholders must align product portfolios and commercial models to the nuanced needs of each geographic territory.

InDepth Analysis of Leading Antithrombin Manufacturers Unveiling Strategic Collaborations Pipeline Developments and Competitive Growth Initiatives

Leading manufacturers in the antithrombin landscape are forging collaborative alliances, expanding production footprints, and advancing pipeline candidates to secure differentiated positions. Companies with established plasma-derived portfolios are enhancing upstream plasma sourcing partnerships and investing in next-generation filter technologies to optimize yield and purity. Simultaneously, recombinant players are accelerating cell line optimization and exploring transgenic expression systems to reduce manufacturing cycle times.

Strategic collaborations between biopharma firms and diagnostic technology developers have emerged as a key trend. By co-developing companion diagnostics that quantify antithrombin activity in real time, these partnerships create integrated solutions that differentiate product offerings and fortify value propositions to large hospital networks.

Pipeline developments are centered on long-acting antithrombin analogs and non-intravenous delivery formats. Several companies are advancing preclinical candidates designed for subcutaneous administration, while others are investigating oral suspension prototypes aimed at chronic management scenarios. Regulatory submissions for these novel dosage forms are expected to set new precedents in trial endpoints and safety assessments.

Competitive growth initiatives extend to geographic expansion in underserved markets and targeted acquisitions that add complementary assay platforms or plasma fractionation facilities. Through these multi-pronged strategies, leading entities are not only safeguarding supply stability but also broadening their therapeutic reach in an increasingly complex antithrombin ecosystem.

Actionable Industry Recommendations for Antithrombin Market Leaders to Enhance Innovation Drive Operational Excellence and Strengthen Competitive Positioning

Industry leaders seeking to capture emerging opportunities in the antithrombin arena should prioritize integrated innovation roadmaps that align R&D, manufacturing, and commercial functions. A proactive investment in advanced expression technologies and protein engineering will enable the design of next-generation antithrombin variants with enhanced stability and tailored pharmacokinetics. This upstream focus must be complemented by downstream process intensification to drive cost efficiencies and maintain competitive pricing.

Simultaneously, cultivating robust relationships with diagnostic solution providers can create end-to-end offerings that differentiate in value-based care models. By embedding antithrombin activity monitoring into digital health platforms, organizations can transition from product suppliers to holistic coagulation management partners, reinforcing customer loyalty and facilitating premium positioning.

Supply chain resilience should also be reinforced through dual sourcing strategies that balance plasma-derived and recombinant streams. Developing strategic alliances with regional plasma collection centers and investing in localized manufacturing hubs can mitigate tariff impacts and reduce lead times, thus enhancing responsiveness to volatile demand patterns.

Finally, adopting a data-driven commercialization approach-leveraging real-world evidence from patient registries and health economics analyses-will support reimbursement negotiations and formulary inclusion. Through these actionable measures, industry stakeholders can navigate regulatory complexity, optimize operational agility, and reinforce their competitive mo

Rigorous Research Methodology Detailing Primary Secondary Data Collection Analytical Frameworks and Expert Validation Processes Underpinning the Antithrombin Market Study

This study employs a rigorous research methodology combining both primary and secondary sources to deliver robust insights into the antithrombin market. Primary research consists of structured interviews and surveys with key opinion leaders in hematology, clinical laboratory directors, procurement officers, and regulatory experts. These qualitative inputs provide firsthand perspectives on emerging trends, unmet needs, and purchasing behaviors across diverse end-user segments.

Secondary research encompasses an exhaustive review of peer-reviewed journals, company annual reports, regulatory filings, and patent databases. These resources establish a foundational understanding of the molecular characteristics, production techniques, and competitive landscapes associated with both plasma-derived and recombinant antithrombin products.

Analytical frameworks such as SWOT (Strengths, Weaknesses, Opportunities, Threats) and Porter’s Five Forces are applied to assess the strategic positioning of leading manufacturers and to identify potential entry barriers. Market segmentation schemas are developed to map demand dynamics by type, source, form, dosage, application, and end user, ensuring holistic coverage of all relevant perspectives.

Findings are validated through expert panels comprising academic researchers, clinician advisors, and industry executives. Statistical triangulation techniques reconcile quantitative shipment data with qualitative feedback, thereby enhancing accuracy and reliability. This integrated approach ensures that the conclusions drawn are both comprehensive and actionable for stakeholders navigating the evolving antithrombin ecosystem.

Concise Synthesis of Antithrombin Market Findings Emphasizing Key Insights Strategic Implications and Opportunities for Future Research and Development

The collective insights into antithrombin underscore a market at the nexus of scientific innovation, regulatory evolution, and shifting economic forces. Technological breakthroughs in recombinant expression and protein engineering are converging with personalized medicine initiatives to redefine therapeutic frameworks. Concurrently, 2025 trade tariffs have catalyzed supply chain realignment, accelerating the adoption of recombinant alternatives and encouraging strategic geographic diversification.

Segmentation analysis has illuminated nuanced demand drivers across molecular types, formulation preferences, therapeutic applications, and end-user environments. Regionally, the Americas, Europe, Middle East and Africa, and Asia-Pacific each present distinct regulatory, infrastructural, and demographic landscapes that must be navigated with tailored entry and growth strategies. Leading manufacturers are responding with strategic collaborations, pipeline innovations, and enhanced manufacturing agility to secure market share.

By implementing targeted recommendations-ranging from advanced R&D investments to integrated diagnostic partnerships and resilient sourcing models-industry participants can position themselves for sustainable growth. The rigorous methodological foundation and expert validation applied in this study ensure that these conclusions are grounded in empirical evidence and practitioner expertise.

Looking ahead, the antithrombin sector offers significant opportunities for value creation, particularly through the development of novel delivery formats and precision medicine approaches. As stakeholders apply the insights provided herein, they will be well equipped to navigate uncertainties and capitalize on the dynamic evolution of coagulation management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Alpha
    • Beta
  • Source
    • Human Plasma
    • Recombinant
  • Form
    • Liquid
    • Powder
  • Dosage Form
    • Injectable
    • Oral Suspensions
  • Therapeutic Application
    • Acquired Deficiency
    • Acute Pancreatitis
    • Congenital Deficiency
    • Disseminated Intravascular Coagulation
    • Liver Disease
    • Sepsis Associated Coagulopathy
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Baxter International Inc.
  • Bio-Techne Corporation
  • Biocon Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • China Biologic Products, Inc.
  • Diapharma Group, Inc.
  • European Medicines Agency
  • F. Hoffmann-La Roche Ltd
  • Genesis BioPharma Services
  • Grifols, S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of recombinant antithrombin therapies on reducing postoperative thrombosis risk in cardiac surgery
5.2. Evaluating global access barriers for recombinant antithrombin products in emerging healthcare markets
5.3. Assessing economic impact of antithrombin deficiency screening programs on healthcare resource utilization
5.4. Adoption trends of point of care antithrombin activity assays in critical care and emergency departments
5.5. Regulatory harmonization challenges for multinational clinical trials involving recombinant antithrombin drugs
5.6. Impact of SARS CoV 2 induced coagulopathy on antithrombin therapy demand and pricing strategies
5.7. Integration of pharmacogenomic data for optimizing antithrombin replacement dosing in high risk thrombosis patients
5.8. Long term safety and efficacy data shaping investor confidence in next generation antithrombin biosimilars
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antithrombin Market, by Type
8.1. Introduction
8.2. Alpha
8.3. Beta
9. Antithrombin Market, by Source
9.1. Introduction
9.2. Human Plasma
9.3. Recombinant
10. Antithrombin Market, by Form
10.1. Introduction
10.2. Liquid
10.3. Powder
11. Antithrombin Market, by Dosage Form
11.1. Introduction
11.2. Injectable
11.3. Oral Suspensions
12. Antithrombin Market, by Therapeutic Application
12.1. Introduction
12.2. Acquired Deficiency
12.3. Acute Pancreatitis
12.4. Congenital Deficiency
12.5. Disseminated Intravascular Coagulation
12.6. Liver Disease
12.7. Sepsis Associated Coagulopathy
13. Antithrombin Market, by End User
13.1. Introduction
13.2. Ambulatory Surgical Centers
13.3. Clinics
13.4. Diagnostic Laboratories
13.5. Hospitals
13.6. Research Institutes
14. Americas Antithrombin Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antithrombin Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antithrombin Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Baxter International Inc.
17.3.2. Bio-Techne Corporation
17.3.3. Biocon Ltd.
17.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
17.3.5. China Biologic Products, Inc.
17.3.6. Diapharma Group, Inc.
17.3.7. European Medicines Agency
17.3.8. F. Hoffmann-La Roche Ltd
17.3.9. Genesis BioPharma Services
17.3.10. Grifols, S.A.
17.3.11. Jiangsu Hengrui Medicine Co., Ltd.
17.3.12. Lee Biosolutions, Inc.
17.3.13. LFB USA, Inc.
17.3.14. Merck KGaA
17.3.15. Novartis AG
17.3.16. Octapharma AG
17.3.17. Pfizer Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTITHROMBIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTITHROMBIN MARKET: RESEARCHAI
FIGURE 28. ANTITHROMBIN MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTITHROMBIN MARKET: RESEARCHCONTACTS
FIGURE 30. ANTITHROMBIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTITHROMBIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTITHROMBIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBIN MARKET SIZE, BY ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBIN MARKET SIZE, BY BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBIN MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBIN MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBIN MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBIN MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACQUIRED DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBIN MARKET SIZE, BY ACUTE PANCREATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBIN MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBIN MARKET SIZE, BY DISSEMINATED INTRAVASCULAR COAGULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTITHROMBIN MARKET SIZE, BY LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTITHROMBIN MARKET SIZE, BY SEPSIS ASSOCIATED COAGULOPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTITHROMBIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTITHROMBIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTITHROMBIN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTITHROMBIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTITHROMBIN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 89. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 90. CANADA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 91. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 92. CANADA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 93. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 94. CANADA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 95. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. CANADA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 104. MEXICO ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 105. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 106. MEXICO ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 107. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 108. MEXICO ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 109. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. MEXICO ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. GERMANY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 163. GERMANY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 166. GERMANY ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 167. GERMANY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. GERMANY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. GERMANY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 170. GERMANY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 171. GERMANY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. GERMANY ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. FRANCE ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 175. FRANCE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 178. FRANCE ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 179. FRANCE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 180. FRANCE ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 181. FRANCE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. FRANCE ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. FRANCE ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. FRANCE ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ITALY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 198. ITALY ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 199. ITALY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 200. ITALY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 201. ITALY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 202. ITALY ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 203. ITALY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. ITALY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ITALY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. ITALY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. ITALY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ITALY ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SPAIN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 211. SPAIN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 214. SPAIN ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 215. SPAIN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. SPAIN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. SPAIN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. SPAIN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. SPAIN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. SPAIN ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. DENMARK ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 259. DENMARK ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 262. DENMARK ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 263. DENMARK ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 264. DENMARK ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 265. DENMARK ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. DENMARK ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. DENMARK ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. DENMARK ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. QATAR ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 282. QATAR ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 283. QATAR ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 284. QATAR ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 285. QATAR ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 286. QATAR ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 287. QATAR ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. QATAR ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. QATAR ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. QATAR ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. QATAR ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. QATAR ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. FINLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 294. FINLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 295. FINLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 297. FINLAND ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 298. FINLAND ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 299. FINLAND ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 300. FINLAND ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 301. FINLAND ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 302. FINLAND ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 303. FINLAND ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. FINLAND ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. EGYPT ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 330. EGYPT ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 331. EGYPT ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 332. EGYPT ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 333. EGYPT ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 334. EGYPT ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 335. EGYPT ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 336. EGYPT ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 337. EGYPT ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 338. EGYPT ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 339. EGYPT ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. EGYPT ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. TURKEY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 342. TURKEY ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 343. TURKEY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 344. TURKEY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 345. TURKEY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 346. TURKEY ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 347. TURKEY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 348. TURKEY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 349. TURKEY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 350. TURKEY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 351. TURKEY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 352. TURKEY ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 353. ISRAEL ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 354. ISRAEL ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 355. ISRAEL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 356. ISRAEL ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 357. ISRAEL ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 358. ISRAEL ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 359. ISRAEL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 360. ISRAEL ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 361. ISRAEL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 362. ISRAEL ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 363. ISRAEL ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 364. ISRAEL ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 365. NORWAY ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 366. NORWAY ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 367. NORWAY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 368. NORWAY ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 369. NORWAY ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 370. NORWAY ANTITHROMBIN MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 371. NORWAY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 372. NORWAY ANTITHROMBIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 373. NORWAY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 374. NORWAY ANTITHROMBIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 375. NORWAY ANTITHROMBIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 376. NORWAY ANTITHROMBIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 377. POLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 378. POLAND ANTITHROMBIN MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 379. POLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 380. POLAND ANTITHROMBIN MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 381. POLAND ANTITHROMBIN MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 382. POLAND ANTITHROMBIN MARKET SIZE, BY F

Samples

Loading
LOADING...

Companies Mentioned

  • Baxter International Inc.
  • Bio-Techne Corporation
  • Biocon Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • China Biologic Products, Inc.
  • Diapharma Group, Inc.
  • European Medicines Agency
  • F. Hoffmann-La Roche Ltd
  • Genesis BioPharma Services
  • Grifols, S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee Biosolutions, Inc.
  • LFB USA, Inc.
  • Merck KGaA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc.

Table Information